HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

This publication has 44 references indexed in Scilit:

• Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial
  Journal of Clinical Oncology, 2009
• Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab
  Annals of Oncology, 2008
• The genomic profile of HER2‐amplified breast cancers: the influence of ER status
  The Journal of Pathology, 2008
• Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells
  British Journal of Cancer, 2007
• American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
  Journal of Clinical Oncology, 2007
• Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes
  Human Pathology, 2006
• Herceptin Sensitizes ErbB2–Overexpressing Cells to Apoptosis by Reducing Antiapoptotic Mcl-1 Expression
  Clinical Cancer Research, 2006
• Correlation of HER-2 Status With Estrogen and Progesterone Receptors and Histologic Features in 3,655 Invasive Breast Carcinomas
  American Journal of Clinical Pathology, 2005
• HER2 Testing in Patients With Breast Cancer: Poor Correlation Between Weak Positivity by Immunohistochemistry and Gene Amplification by Fluorescence In Situ Hybridization
  Mayo Clinic Proceedings, 2002
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
  Proceedings of the National Academy of Sciences, 2001